Static Model-Based Assessment of OATP1B1-Mediated Drug Interactions with Preincubation-Dependent Inhibitors Based on Inactivation and Recovery Kinetics

被引:7
|
作者
Taguchi, Takayuki [1 ,2 ]
Masuo, Yusuke [2 ]
Futatsugi, Azusa [2 ]
Kato, Yukio [2 ]
机构
[1] Kaken Pharmaceut Co Ltd, Pharmacokinet & Safety Dept, Drug Res Ctr, Kyoto, Japan
[2] Kanazawa Univ, Fac Pharm, Inst Med Pharmaceut & Hlth Sci, Kakumamachi, Kanazawa, Ishikawa 9201102, Japan
关键词
HEPATIC-UPTAKE; PREDICTION; OATP; PHARMACOKINETICS; TRANSPORTER; IMPACT; IRINOTECAN; PROFILES;
D O I
10.1124/dmd.120.000020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Quantitative assessment of drug-drug interactions (DDIs) via organic anion transporting polypeptide (OATP) 1B1 is one of the key issues in drug development. Although OATP1B1 inhibition exhibits unique characteristics, including preincubation dependence for some inhibitors, a limited approach has been attempted based on the static model that considers such preincubation dependence in the prediction of DDIs via OATP1B1. The present study aimed to establish the prediction of DDIs via OATP1B1 using preincubation-dependent inhibitors based on the static model and incorporating both inactivation and recovery of OATP1B1 activity. Cyclosporine A was selected as a preincubation-dependent inhibitor, as well as five substrates that include probes and pharmaceuticals. The inhibition ratio (R value) calculated on the basis of a conventional static model, considering inhibition of OATP1B1 and contribution ratio of OATP1B1 to the overall hepatic uptake, was much lower than the reported AUC ratio, even when IC50 values were estimated after preincubation conditions. Conversely, the R value that was estimated by considering inactivation and recovery parameters was closer to the AUC ratio. The R value that was calculated assuming the complete contribution of OATP1B1 was much higher than the AUC ratio, avoiding false-negative prediction. The R value estimated by considering inactivation and recovery for another combination of a preincubation-dependent inhibitor, asunaprevir, and substrate drug, rosuvastatin, was also closer to the AUC ratio. Thus, R values calculated based on such OATP1B1 kinetics would be potential alternative indexes for the quantitative prediction of OATP1B1-mediated DDIs using preincubation-dependent inhibitors, although this prediction is affected by estimation of the contribution ratio of substrates. SIGNIFICANCE STATEMENT Static model-based quantitative prediction of organic anion transporting polypeptide 1B1-mediated drug-drug interactions induced by preincubation-dependent inhibitors was newly proposed to avoid false-negative prediction.
引用
收藏
页码:750 / 758
页数:9
相关论文
共 38 条
  • [1] IMPAIRED OATP1B1-MEDIATED TRANSPORT FOLLOWING TREATMENT WITH LYSOSOMOTROPIC DRUG CHLOROQUINE: IMPLICATIONS IN OATP-MEDIATED DRUGeDRUG INTERACTIONS
    Yue, Wei
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S12 - S12
  • [2] Differential Preincubation Effects of Nicardipine on OATP1B1-and OATP1B3-Mediated Transport in the Presence and Absence of Protein: Implications in Assessing OATP1B1-and OATP1B3-Mediated Drug-Drug Interactions
    Kayesh, Ruhul
    Tambe, Vishakha
    Xu, Chao
    Yue, Wei
    PHARMACEUTICS, 2023, 15 (03)
  • [3] Down-Regulation of OATP1B1-Mediated Transport by Mammalian Target of Rapamycin (mTOR) Inhibitors Everolimus and Sirolimus: Potential Mechanism and Implication in OATP-Mediated Drug-Drug Interactions
    Farasyn, Taleah
    Pahwa, Sonia
    Wang, Xueying
    Zhang, Pengyue
    Ding, Kai
    Li, Lang
    Yue, Wei
    FASEB JOURNAL, 2017, 31
  • [4] Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
    Garrison, Dominique A.
    Talebi, Zahra
    Eisenmann, Eric D.
    Sparreboom, Alex
    Baker, Sharyn D.
    PHARMACEUTICS, 2020, 12 (09) : 1 - 18
  • [5] Quantitative Prediction of OATP-Mediated Drug-Drug Interactions With Model-Based Analysis of Endogenous Biomarker Kinetics
    Yoshida, Kenta
    Guo, Cen
    Sane, Rucha
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2018, 7 (08): : 517 - 524
  • [6] Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs
    Mochizuki, Tatsuki
    Aoki, Yasunori
    Yoshikado, Takashi
    Yoshida, Kenta
    Lai, Yurong
    Hirabayashi, Hideki
    Yamaura, Yoshiyuki
    Rockich, Kevin
    Taskar, Kunal
    Takashima, Tadayuki
    Chu, Xiaoyan
    Zamek-Gliszczynski, Maciej J.
    Mao, Jialin
    Maeda, Kazuya
    Furihata, Kenichi
    Sugiyama, Yuichi
    Kusuhara, Hiroyuki
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (06): : 1519 - 1531
  • [7] Generation of Bayesian prediction models for OATP-mediated drug-drug interactions based on inhibition screen of OATP1B1, OATP1B1*15 and OATP1B3
    van de Steeg, E.
    Venhorst, J.
    Jansen, H. T.
    Nooijen, I. H. G.
    DeGroot, J.
    Wortelboer, H. M.
    Vlaming, M. L. H.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 70 : 29 - 36
  • [8] Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1-and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1-and OATP1B3-Mediated Drug-Drug Interactions
    Farasyn, Taleah
    Crowe, Alexandra
    Hatley, Oliver
    Neuhoff, Sibylle
    Alam, Khondoker
    Kanyo, Jean
    Lam, TuKiet T.
    Ding, Kai
    Yue, Wei
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (10) : 3443 - 3456
  • [9] Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions
    Kimoto, Emi
    Costales, Chester
    West, Mark A.
    Bi, Yi-an
    Vourvahis, Manoli
    Rodrigues, A. David
    Varma, Manthena V. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (02) : 404 - 415
  • [10] Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3
    Bednarczyk, Dallas
    ANALYTICAL BIOCHEMISTRY, 2010, 405 (01) : 50 - 58